hMAGEA2 promotes progression of breast cancer by regulating Akt and Erk1/2 pathways

作者：Park Song; Sung Yonghun; Jeong Jain; Choi Minjee; Lee Jinhee; Kwon Wookbong; Jang Soyoung; Park Si Jun; Kim Hyeng Soo; Lee Mee Hyun; Kim Dong Joon; Liu Kangdong; Kim Sung Hyun; Dong Zigang; Ryoo Zae Young^*; Kim Myoung Ok^*

来源：Oncotarget, 2017, 8(23): 37115-37127.

DOI：10.18632/oncotarget.16184

• hMAGEA2
• breast cancer
• triple-negative breast cancer
• metastasis
• Akt

Breast cancer is the most abundant cancer worldwide and a severe problem for women. Notably, breast cancer has a high mortality rate, mainly because of tumor progression and metastasis. Triple-negative breast cancer (TNBC) is highly progressive and lacks the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Therefore, there are no established therapeutic targets against TNBC. In this study, we investigated whether the expression of human melanoma-associated antigen A2 (MAGEA2) is associated with TNBC. We found that hMAGEA2 is significantly overexpressed in human TNBC tissues; we also observed oncogenic properties using TNBC cell lines (MDA-MB-231 and MDA-MB-468). The overexpression of hMAGEA2 in MDA-MB-231 cell line showed dramatically increased cellular proliferation, colony formation, invasion, and xenograft tumor formation and growth. Conversely, knockdown of hMAEGA2 in MDA-MB-468 cell line suppressed cellular proliferation, colony formation, and xenograft tumor formation. Additionally, we showed that hMAGEA2 regulated the activation of Akt and Erk1/2 signaling pathways. These data indicate that hMAGEA2 is important for progression of TNBC and may serve as a novel molecular therapeutic target.

• 出版日期2017-6-6